Enterprise Value

23.69M

Cash

285.6M

Avg Qtr Burn

-13.01M

Short % of Float

15.29%

Insider Ownership

1.71%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2a

Update

TERN-201 (VAP-1 inhibitor) Details
Non-alcoholic steatohepatitis

Phase 1b

Update

Phase 1

Data readout

TERN-701 (Allosteric BCR-ABL inhib) Details
Chronic myelomonocytic leukemia

Phase 1

Initiation

TERN-101 (FXR agonist) Details
Non-alcoholic steatohepatitis

Failed

Discontinued